This is an early access version, the complete PDF, HTML, and XML versions will be available soon.
Open AccessReview
Lapatinib-Based Radioagents for Application in Nuclear Medicine
by
Przemysław Koźmiński
Przemysław Koźmiński
Dr. Przemysław Koźmiński, Ph.D., holds the position of Adjunct Professor at the Institute of and [...]
Dr. Przemysław Koźmiński, Ph.D., holds the position of Adjunct Professor at the Institute of Nuclear Chemistry and Technology (INCT). He earned his Master of Science degree from the Faculty of Chemistry at the University of Warsaw in 2004 and subsequently obtained his Doctorate from the Centre for Radiochemistry and Nuclear Chemistry at the Institute of Nuclear Chemistry and Technology in 2012. His research predominantly focuses on the design of radiopharmaceuticals for nuclear medicine, with particular emphasis on the synthesis and evaluation of novel radiotracers for disease imaging and therapeutic applications, specifically concerning cancer and Alzheimer's disease.
and
Ewa Gniazdowska
Ewa Gniazdowska
Dr. Ewa Gniazdowska, D.Sc., is a Professor at the Institute of Nuclear Chemistry and Technology She [...]
Dr. Ewa Gniazdowska, D.Sc., is a Professor at the Institute of Nuclear Chemistry and Technology (INCT). She holds a Master of Science degree in Chemistry from Warsaw University and has attained both a Ph.D. and a D.Sc. in Chemistry from the Institute of Nuclear Chemistry and Technology. Her principal research interests are centered on radiopharmacy and the development of radiopharmaceuticals for nuclear medicine.
Centre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, 03-195 Warsaw, Poland
*
Authors to whom correspondence should be addressed.
Appl. Sci. 2025, 15(20), 10964; https://doi.org/10.3390/app152010964 (registering DOI)
Submission received: 9 September 2025
/
Revised: 10 October 2025
/
Accepted: 11 October 2025
/
Published: 12 October 2025
Abstract
Lapatinib is an approved therapeutic agent for the treatment of HER2-positive breast cancer. It has a high affinity for the non-receptor cytoplasmic tyrosine kinases of the EGFR and HER2 receptors. It is a type II inhibitor, with Kiapp values of 3 nM and 13 nM, respectively. The dissociation rate of the lapatinib–receptor complex is notably slow compared with many other kinase inhibitors. Although the literature contains numerous reports on radiolabelled ligands for HER-family receptors, studies on radiolabelled tyrosine kinase inhibitors are far fewer, and only few focus specifically on radiolabelled lapatinib. The aim of this review is to compile and discuss the chemical and biological data on lapatinib-based radiopharmaceuticals with potential applications in the diagnosis and treatment of HER2-positive tumours.
Share and Cite
MDPI and ACS Style
Koźmiński, P.; Gniazdowska, E.
Lapatinib-Based Radioagents for Application in Nuclear Medicine. Appl. Sci. 2025, 15, 10964.
https://doi.org/10.3390/app152010964
AMA Style
Koźmiński P, Gniazdowska E.
Lapatinib-Based Radioagents for Application in Nuclear Medicine. Applied Sciences. 2025; 15(20):10964.
https://doi.org/10.3390/app152010964
Chicago/Turabian Style
Koźmiński, Przemysław, and Ewa Gniazdowska.
2025. "Lapatinib-Based Radioagents for Application in Nuclear Medicine" Applied Sciences 15, no. 20: 10964.
https://doi.org/10.3390/app152010964
APA Style
Koźmiński, P., & Gniazdowska, E.
(2025). Lapatinib-Based Radioagents for Application in Nuclear Medicine. Applied Sciences, 15(20), 10964.
https://doi.org/10.3390/app152010964
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details
here.
Article Metrics
Article metric data becomes available approximately 24 hours after publication online.
